RCKT
Rocket Pharmaceuticals, Inc.
$3.44
+0.03 (+0.88%)
At close · Jul 17
Market Cap
$375.63M
Shares
109,193,549
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2025
Net Income
-$223.12M
+13.8%
FY2025
Diluted EPS
-$2.01
+26.4%
FY2025
Operating Cash Flow
-$190.01M
+9.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | |
| $1M | $1.1M | $1.5M | $1.4M | $900K | $1.1M | $900K | $900K | — | — | — | — | — | |
| $137.53M | $142.02M | $171.24M | $186.34M | $165.57M | $125.48M | $105.44M | $57.91M | $53.27M | $14.92M | $5.99M | $12.55M | $5.59M | |
| $75.11M | $86.5M | $101.96M | $73.32M | $58.77M | $41.77M | $28.87M | $18.24M | $17.89M | $4.86M | $1.58M | $7.84M | $2.11M | |
| — | $8.9M | $7.2M | $4.9M | $3.9M | $3.2M | $1.15M | $426K | $330K | — | — | — | — | |
| — | $3.23M | $0 | — | — | — | — | — | — | — | — | — | — | |
| $215.87M | $231.75M | $273.21M | $259.66M | $224.34M | $167.25M | $134.3M | $76.15M | $71.16M | $19.77M | $7.57M | — | — | |
| -$215.87M | -$231.75M | -$273.21M | -$259.66M | -$224.34M | -$167.25M | -$134.3M | -$76.15M | -$71.16M | -$19.77M | -$7.57M | -$20.4M | -$7.7M | |
| — | -$222.85M | -$266.01M | -$254.76M | -$220.44M | -$164.05M | -$133.16M | -$75.73M | -$70.83M | — | — | — | — | |
| $1.89M | $1.89M | $1.89M | $1.88M | $1.86M | $2.98M | $6.97M | $5.96M | $6.04M | $0 | $0 | $1.23M | $980K | |
| $2.04M | — | — | — | — | — | — | — | — | $819K | $443K | $89K | — | |
| — | — | — | — | $2.48M | -$1.82M | -$5.4M | — | — | — | — | — | — | |
| — | -$223.12M | -$258.75M | — | — | — | — | — | — | — | — | — | — | |
| — | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| -$209.38M | -$223.12M | -$258.75M | -$245.6M | -$221.86M | -$169.07M | -$139.7M | -$77.27M | -$74.52M | -$19.58M | -$7.57M | -$67.98M | -$9.53M | |
| -$209.38M | -$223.12M | -$258.75M | -$245.6M | -$221.86M | -$169.07M | -$139.7M | -$77.27M | -$74.52M | -$19.58M | -$7.57M | -$68.11M | -$13.8M | |
| -$209.47M | -$223.22M | -$259M | -$244.92M | -$222.06M | -$169.19M | -$139.76M | -$77.12M | -$74.65M | -$19.58M | -$7.57M | — | — | |
| USD/shares | — | -$2.01 | -$2.73 | -$2.92 | -$3.26 | -$2.67 | -$2.52 | -$1.58 | — | — | — | — | — |
| USD/shares | — | -$2.01 | -$2.73 | -$2.92 | -$3.26 | -$2.67 | -$2.52 | -$1.58 | — | — | — | — | — |
| shares | — | 111.12M | 94.81M | 84.01M | 68.15M | 63.24M | 55.38M | 49.01M | 39.38M | 6.8M | 6.83M | 18.31M | 1.02M |
| shares | — | 111.12M | 94.81M | 84.01M | 68.15M | 63.24M | 55.38M | 49.01M | 39.38M | 6.8M | 6.83M | 18.31M | 1.02M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2021: $72K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.75×
EV/EBIT
—
Biotechnology median 26.36×
P/E (TTM)
—
Biotechnology median 7.37×
Key facts
CIK
1281895
CUSIP
77313F106
13F (30d)
14 filings
13 filers
Visit website
Investor relations